PT  - JOURNAL ARTICLE
AU  - Whittaker, Charles
AU  - Watson, Oliver J.
AU  - Alvarez-Moreno, Carlos
AU  - Angkasekwinai, Nasikarn
AU  - Boonyasiri, Adhiratha
AU  - Triana, Luis Carlos
AU  - Chanda, Duncan
AU  - Charoenpong, Lantharita
AU  - Chayakulkeeree, Methee
AU  - Cooke, Graham S.
AU  - Croda, Julio
AU  - Cucunubá, Zulma M
AU  - Djaafara, Bimandra A.
AU  - Estofolete, Cassia F.
AU  - Grillet, Maria Eugenia
AU  - Faria, Nuno R.
AU  - Costa, Silvia Figueiredo
AU  - Forero-Peña, David A.
AU  - Gibb, Diana M.
AU  - Gordon, Anthony C
AU  - Hamers, Raph L.
AU  - Hamlet, Arran
AU  - Irawany, Vera
AU  - Jitmuang, Anupop
AU  - Keurueangkul, Nukool
AU  - Kimani, Teresia Njoki
AU  - Lampo, Margarita
AU  - Levin, Anna S.
AU  - Lopardo, Gustavo
AU  - Mustafa, Rima
AU  - Nayagam, Shevanthi
AU  - Ngamprasertchai, Thundon
AU  - Hannah Njeri, Ng’ang’a Irene
AU  - Nogueira, Mauricio L.
AU  - Ortiz-Prado, Esteban
AU  - Perroud, Mauricio W.
AU  - Phillips, Andrew N.
AU  - Promsin, Panuwat
AU  - Qavi, Ambar
AU  - Rodger, Alison J.
AU  - Sabino, Ester C.
AU  - Sangkaew, Sorawat
AU  - Sari, Djayanti
AU  - Sirijatuphat, Rujipas
AU  - Sposito, Andrei C.
AU  - Srisangthong, Pratthana
AU  - Thompson, Hayley A.
AU  - Udwadia, Zarir
AU  - Valderrama-Beltrán, Sandra
AU  - Winskill, Peter
AU  - Ghani, Azra C.
AU  - Walker, Patrick G.T.
AU  - Hallett, Timothy B.
TI  - Understanding the Potential Impact of Different Drug Properties On SARS-CoV-2 Transmission and Disease Burden: A Modelling Analysis
AID  - 10.1101/2021.06.17.21259078
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.17.21259078
4099  - http://medrxiv.org/content/early/2021/06/20/2021.06.17.21259078.short
4100  - http://medrxiv.org/content/early/2021/06/20/2021.06.17.21259078.full
AB  - Background The unprecedented public health impact of the COVID-19 pandemic has motivated a rapid search for potential therapeutics, with some key successes. However, the potential impact of different treatments, and consequently research and procurement priorities, have not been clear.Methods and Findings We develop a mathematical model of SARS-CoV-2 transmission, COVID-19 disease and clinical care to explore the potential public-health impact of a range of different potential therapeutics, under a range of different scenarios varying: i) healthcare capacity, ii) epidemic trajectories; and iii) drug efficacy in the absence of supportive care. In each case, the outcome of interest was the number of COVID-19 deaths averted in scenarios with the therapeutic compared to scenarios without. We find the impact of drugs like dexamethasone (which are delivered to the most critically-ill in hospital and whose therapeutic benefit is expected to depend on the availability of supportive care such as oxygen and mechanical ventilation) is likely to be limited in settings where healthcare capacity is lowest or where uncontrolled epidemics result in hospitals being overwhelmed. As such, it may avert 22% of deaths in high-income countries but only 8% in low-income countries (assuming R=1.35). Therapeutics for different patient populations (those not in hospital, early in the course of infection) and types of benefit (reducing disease severity or infectiousness, preventing hospitalisation) could have much greater benefits, particularly in resource-poor settings facing large epidemics.Conclusions There is a global asymmetry in who is likely to benefit from advances in the treatment of COVID-19 to date, which have been focussed on hospitalised-patients and predicated on an assumption of adequate access to supportive care. Therapeutics that can feasibly be delivered to those earlier in the course of infection that reduce the need for healthcare or reduce infectiousness could have significant impact, and research into their efficacy and means of delivery should be a priority.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCW is supported by a Medical Research Council Doctoral Training Partnership Studentship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and outputs relevant to the analysis are available at https://github.com/mrc-ide/apothecary. https://github.com/mrc-ide/apothecary